🇺🇸 valsartan plus hydrochlorothiazide in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Back Pain — 1 report (10%)
  2. Bladder Cancer — 1 report (10%)
  3. Bladder Transitional Cell Carcinoma — 1 report (10%)
  4. Bladder Transitional Cell Carcinoma Recurrent — 1 report (10%)
  5. Dehydration — 1 report (10%)
  6. Drug Interaction — 1 report (10%)
  7. Drug Level Increased — 1 report (10%)
  8. Erythema — 1 report (10%)
  9. Feeling Hot — 1 report (10%)
  10. Foetal Exposure During Pregnancy — 1 report (10%)

Source database →

valsartan plus hydrochlorothiazide in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is valsartan plus hydrochlorothiazide approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for valsartan plus hydrochlorothiazide in United States?

Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.